As more big pharma firms join Novo Nordisk and Eli Lilly in the obesity drug race, they might want to pay attention to consumption patterns in Brazil, South America’s largest market, that are influencing commercial, legal and regulatory decisions.
As more big pharma firms join Novo Nordisk and Eli Lilly in the obesity drug race, they might want to pay attention to consumption patterns in Brazil, South America’s largest market, that are influencing commercial, legal and regulatory decisions.